anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention discloses methods for identifying Francisella tularensis vaccine candidates. It enables identification of novel vaccine candidates and quality assurance for vaccine batches, assessment of protection in vaccinates and identification of the infecting agent in vaccinates. Mice were first vaccinated with Brucella abortus O-polysaccharide (OPS) vaccine. These animals were then given 10 LD50s of F.  tularensis live vaccine strain (LVS). Sixty percent (60%) of the vaccinated mice survived the multiple lethal doses. Sera were collected from these surviving mice and the antibodies were used to probe supernatant and cell lysates of live F. tularensis LVS  cultures. Several F. tularensis components were identified only by the noted "survivor"  antisera. Of these identified proteins, enzyme digestions and chemical oxidation suggest post-translational modifications of some proteins e.g. a 52 kDa glycoprotein, a 45 kDa lipoprotein and a 19 kDa nucleoprotein. The 52 kDa component caused nitrous oxide induction in tissue cultures at low concentrations, cell death at high concentrations. Vaccination with this gave partial protection while addition of other components acted synergistically to give enhanced protection from 250 LD50s of F. tularensis LVS.
BACKGROUND/PURPOSE: The eighth edition of the AJCC staging system introduced a shift in the staging of distal bile duct cancer (DBC), emphasizing the depth of invasion over adjacent organ invasion. This study aimed to evaluate the clinical impact of pancreatic invasion in pT1-stage DBC and identify prognostic factors for long-term survival.
METHODS: This multicenter retrospective analysis encompassed DBC patients who underwent pancreaticoduodenectomy between 2009 and 2019 in six Korean tertiary centers, specifically those with final pathology confirming AJCC eighth edition T1 stage and intrapancreatic bile duct tumor origin. Primary endpoints were five-year recurrence-free survival (RFS) and overall survival (OS). Secondary objectives included the identification of prognostic determinants.
RESULTS: This study involved 287 patients, comprising 190 without and 97 with pancreatic invasion. Pancreatic invasion did not significantly influence five-year OS and RFS rates (OS: without pancreatic invasion 69.9% vs. with pancreatic invasion 54.1%, p = .25; RFS: 56.3% vs. 55.4%, p = .97). Multivariate analysis highlighted male gender, age, lymphovascular invasion, and N stage as significant OS determinants. Notably, male gender, ampulla of Vater invasion, lymphovascular invasion, and N1 stage were also associated with RFS.
CONCLUSIONS: In pT1 DBC, pancreatic invasion demonstrates no substantial impact on long-term prognosis, in accordance with the depth-based paradigm of the eighth edition AJCC staging system. The prognostic factors influencing OS were identified as male gender, age, lymphovascular invasion, and nodal metastasis.
The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
This is a multicenter, randomized, double-blind, parallel-group study of bifeprunox in the treatment of outpatients with schizophrenia, with olanzapine as the active comparator. Subjects must be stable for 3 months or more of treatment with olanzapine at baseline. There will be 2 treatment arms in this study, approximately 60 subjects per arm. After randomization and blinding, each subject will either remain on olanzapine or switch to bifeprunox. Assessments, including body weight and waist measurements, will be made at each study visit.Subjects will participate in the study for approximately 11 weeks. After a screening period of 6 to 14 days, eligible subjects will be treated for 8 weeks. Subjects who do not enter the long-term extension will return for a follow-up visit 7 days after discontinuing the use of test article. Subjects who do enter the long-term extension will have a 7-day taper/titration period after the 8 weeks of double-blind treatment.
The invention relates to a traditional Chinese medicine preparation with capabilities of lowering four high and expelling toxin as well as preparation and taking methods of the traditional Chinese medicine preparation. The traditional Chinese medicine preparation is used for lowering hyperglycemia, hypertension, hyperlipemia, high blood viscosity, vascular plaque and fatty liver, has functions of promoting qi, activating blood and activating and repairing pancreas islet and is also capable of expelling toxins of liver, lung, pancreas, stomach, kidney, excrement and urine. The preparation method comprises the following steps of medicine selecting, cleaning, soaking, purification, distillation, packageing and the like. The traditional Chinese medicine preparation is warmly taken by being diluted when being taken. With the adoption of the traditional Chinese medicine preparation, the traditional Chinese medicine theory is introduced into the field of treating modern molecular cytology diseases, curative medical thoughts of the existing traditional Chinese medicines are surpassed, and a mode of singly using the traditional Chinese medicine preparation or using the traditional Chinese medicine preparation in a combination way can be adopted to carry out administration treatment aiming at different diseases. The traditional Chinese medicine preparation can accurately carry out comprehensive and overall treatment on difficult miscellaneous diseases and is capable of regulating viscera unbalancing and index deviation in large scale. The prescription adopts mucosa absorption and is fast in effect. With the adoption of the traditional Chinese medicine preparation, pharmaceutical preparation technology is simple, and recipe and taking direction are simple, so that a patient easily accepts the traditional Chinese medicine preparation. In addition, the traditional Chinese medicine preparation is easy to carry due to small packages.
PROBLEM TO BE SOLVED: To provide the subject new non-toxic substance produced by a specific microorganism of the genus Streptomyces, active as an antibiotic substance, having high tolerance and effectively inhibiting human immunodeficiency virus. SOLUTION: This substance is a compound of the formula, its salt or its chemically equivalent substance. It has the following properties. Appearance, colorless; solubility, soluble in methanol, acetonitrile and water; stability, stable under neutral or moderately alkaline conditions and unstable in strongly acidic or strongly alkaline solution; molecular formula, C95 H97 N13 O30 ; molecular weight, 1900.90; etc. The compound can be produced by the fermentation with a microorganism HAG 4674 (DSM 11171) of the genus Streptomyces, its variant or mutant. The fermentation is preferably carried out in a nutrient solution containing 1-2% of oat flake and a minor element solution of 0.2-0.3% concentration under aerobic condition at 25-30 deg.C and pH5.5-8.5 for 24-140hr.
An abrupt pressure change applied to a dispersion of core and shell material in a liquid carrier medium encapsulates the core material within the shell material. The method and apparatus of this invention permit a wider range of core and shell materials to be utilized than was possible with prior art methods including materials which previously have not been usable as shell materials. Materials in solid, liquid, gas or multiphase form may be encapsulated. Additionally, capsules are produced in a small fraction of the time required by prior art methods. The total time to perform the encapsulation may range from a few seconds to only a few minutes. The abrupt pressure change may be applied to the dispersion by either a piston or ultrasonic apparatus in both batch, semi-continuous, and continuous processes. Recycling of the capsules through the apparatuses permits adjustment of the capsules' characteristics as well as formation of multiple core capsules.
Phentermine is a Schedule IV controlled substance.

###  9.2 Abuse 

Phentermine is related chemically and pharmacologically to the amphetamines. Amphetamines and other stimulant drugs have been extensively abused and the possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program.

###  9.3 Dependence 

Abuse of amphetamines and related drugs may be associated with intense psychological dependence and severe social dysfunction. There are reports of patients who have increased the dosage of these drugs to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. A severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.
The majority of head and neck cancer patients present with more advanced stages III or IV disease. The treatment of cancers of the head and neck can have profound consequences with regard to functional abilities such as speech and eating. In the treatment of both locally advanced HNSCC and sites where organ preservation is desirable, radiation therapy has been a major method of treatment. However, as a single modality, radiation therapy can cure fewer than 30% of patients with advanced disease. Attempts to improve the outcome of locally advanced HNSCC have generally added chemotherapy to radiotherapy. However, the optimal manner to integrate chemotherapy into the plan of care has been controversial. Chemotherapy has been used most commonly as either induction therapy preceding radiation, or more recently as concomitant therapy along with radiation. Induction chemotherapy has been associated with high response rates of 60-90%, but no significant change in loco-regional control or survival.Clinical trials incorporating chemotherapy with concurrent radiation have recently generated considerable interest. To accomplish both loco-regional control and reduce systemic metastasis, this trial proposes induction chemotherapy followed by concomitant chemotherapy-radiation with an escalating dose of docetaxel in patients with locally advanced previously untreated HNSCC.
The invention relates to the medical technological industry, in particular to a cataplasm for treating infusion phlebitis. The cataplasm comprises an anti-sticking layer, a medicine paste body and a lining layer. The medicine paste body consists of medicines and a cataplasm matrix. The adopted machines are 5 to 10 parts of a rhubarb extract and 3 to 5 parts of borneol. The cataplasm matrix comprises the following ingredients in parts by weight: 4 to 6 parts of carbomer, 4 to 6 parts of sodium polyacrylate, 0.8 to 1.2 parts of gelatin, 5 to 8 parts of kaolin, 0.8 to 1.2 parts of PVPP (Polyvinylpyrrolidone), 0.07 to 0.13 parts of aluminum glycinate, 0.015 to 0.02 parts of tartaric acid, 4 to 6 parts of triethanolamine, 30 to 60 parts of glycerin and 40 to 60 parts of distilled water. According to the cataplasm for treating the infusion phlebitis, the rhubarb and the borneol are combined, so that the effects of relieving swelling and pain, cooling blood, eliminating carbuncle, purging heat and toxicity and removing stagnancy can be achieved. The symptom of the burning pain of a patient suffering from the phlebitis can be quickly and effectively relieved, and healing recovery is promoted. Moreover, the treatment cost is low, the cataplasm is convenient to use, frequent dressing change is avoided, and the operation burden of medical staff is alleviated.
BACKGROUND: Red blood cells (RBCs) transfusion is related to perioperative neurocognitive disorders. The toxic effect of free heme has been identified in many pathologies. However, the underlying mechanisms of RBCs transfusion or free heme in cognitive impairment have not been clearly explored. Therefore, this research was conducted to determine the mechanism of free heme-induced neuroinflammation and cognitive impairment.
METHODS: Rats were received intraperitoneal injection of hemin alone or combined with intracerebroventricular injection of Hemopexin (HPX), and MWM test was conducted to measure cognitive function. The amount of heme-HPX complexes was evaluated by flow cytometry for CD91 + cells. The microglial inflammatory response in rat brain was observed by immunofluorescence staining of Iba-1, and the inflammatory factors of TNF-α, IL-1β and IL-6 in rat brain and BV2 cells were detected by ELISA analysis. Furthermore, neuronal apoptosis in HT22 cells alone and in HT22 + BV2 coculture system was detected by flow cytometry and immunofluorescence staining. Finally, western blot was conducted to detect TLR4/MyD88/NF-κB proteins in rat brain and BV2 cells treated with hemin or combined with pathway inhibitors. Additionally, the M1 surface marker CD86 was observed in BV2 cells to further confirm neuroinflammation.
RESULTS: Intraperitoneal injection of hemin induced cognitive impairment, increase of CD91 + cells, up-regulation of TNF-α and IL-1β, down-regulation of IL-6, activation of microglia, and activation of the TLR4/MyD88/NF-κB signaling pathway in rat brain. Significantly, intracerebroventricular injection of HPX reduced the above effects. Hemin induced boost of TNF-α, IL-1β and IL-6 in BV2 cells, as well as apoptosis in HT22 cells. Notably, when HT22 cells were cocultured with BV2 cells, apoptosis was significantly increased. Hemin also induced activation of the TLR4/MyD88/NF-κB signaling pathway and increased the M1 surface marker CD86 in BV2 cells, and inhibiting this pathway reduced the inflammatory responses.
CONCLUSIONS: Free heme induces cognitive impairment, and the underlying mechanism may involve neuronal apoptosis and microglial inflammation via the TLR4/MyD88/NF-κB signaling pathway. HPX may have potential therapeutic effects. Video Abstract.
All the patients enrolled in the study will receive the standard of care with respect to surgical prosthetic replacement of the diseased hip. The patients will receive a custom-modified (RSA marked) hydroxyapatite-coated prosthesis with ceramic-on-ceramic bearing surfaces (SYMAX-TRIDENT, Stryker). The prosthesis modification provided by the manufacturer has a CE mark. The patients in the active-treatment group will receive a single 5 mg dose of zoledronic acid intravenously just prior to release from the hospital (about 5th day post-surgery) as an adjunct therapy. The control group will receive a placebo (saline) infusion. The active and placebo infusion vials will be provided by Norvartis Pharmaceutical. After surgery, before the administration of zoledronic acid or placebo, each patient will be re-screened for the level of serum calcium. In the case of postoperative hypocalcemia, the infusion will be postponed for a minimum of 3-4 weeks and the infusion will be given after the repeated measurements of serum calcium. All patients will receive calcium and D-vitamin supplementation throughout the study period. Efficacy will be assessed on the basis of clinical, radiographic (RSA, DXA, Spiral CT, conventional radiography) and laboratory criteria. The clinical benefit of zoledronic acid therapy is defined in terms of faster functional recovery, which will be analyzed in two ways: (1) the functional outcome (muscle strength, gait analysis and pedometry) will be repeatedly evaluated before and after surgery, and (2) the subjective outcome of the procedure as well as the general health assessment will be determined at each follow-up visits using standardized outcome measures. The primary objective of this study is to test whether a single infusion of zoledronic acid reduces periprosthetic bone loss measured by DXA at 12 months. Statistical significance of differences in periprosthetic bone mineral density between active-treatment and placebo groups will be analyzed using repeated analysis of variance.
BACKGROUND: Fatigue is a common symptom in cerebral small vessel disease (SVD), but its pathogenesis is poorly understood. It has been suggested that inflammation may play a role. We determined whether central (neuro) inflammation and peripheral inflammation were associated with fatigue in SVD.
METHODS: Notably, 36 patients with moderate-to-severe SVD underwent neuropsychometric testing, combined positron emission tomography and magnetic resonance imaging (PET-MRI) scan, and blood draw for the analysis of inflammatory blood biomarkers. Microglial signal was taken as a proxy for neuroinflammation, assessed with radioligand 11C-PK11195. Of these, 30 subjects had full PET datasets for analysis. We assessed global 11C-PK11195 binding and hotspots of 11C-PK11195 binding in the normal-appearing white matter, lesioned tissue, and combined total white matter. Peripheral inflammation was assessed with serum C-reactive protein (CRP) and using the Olink cardiovascular III proteomic panel comprising 92 biomarkers of cardiovascular inflammation and endothelial activation. Fatigue was assessed using the fatigue severity scale (FSS), the visual analog fatigue scale, and a subscale of the Geriatric Depression Scale.
RESULTS: Mean (SD) age was 68.7 (11.2) years, and 63.9% were male. Of these, 55.6% showed fatigue on the FSS. Fatigued participants had higher disability scores (p = 0.02), higher total GDS scores (p = 0.02), and more commonly reported a history of depression (p = 0.04). 11C-PK11195 ligand binding in the white matter was not associated with any measure of fatigue. Serum CRP was significantly associated with average fatigue score on FSS (ρ = 0.48, p = 0.004); this association persisted when controlling for age, sex, disability score, and depression (β = 0.49, 95% CI (0.17, 2.26), p = 0.03). Blood biomarkers from the Olink panel showed no association with fatigue.
CONCLUSION: In symptomatic SVD patients, neuroinflammation, assessed with microglial marker 11C-PK11195, was not associated with fatigue. We found some evidence for a role of systematic inflammation, evidenced by an association between fatigue severity and raised CRP, but further studies are required to understand this relationship and inform whether it could be therapeutically modified to reduce fatigue severity.
DATA ACCESS STATEMENT: Data for this study are available from the corresponding author upon reasonable request.
Social benefits: This technology has minimal harm (skin sampling diameter of 1mm), rather than surgical traumatic brain biopsy, which meets the minimum harm and maximum benefit; 1) Clear clinical diagnosis and differential diagnosis of diseases at once, avoiding repetitive examinations, effectively saving medical expenses and medical insurance funds; 2) Beneficial for early diagnosis and intervention, reducing social and economic burden; 3) Enhance the disease diagnosis and treatment capabilities of the region, enhance basic medical research, and enhance the medical level of the region. Clinical advantage: This technology belongs to extracranial tissues α-Syn aggregate testing can replace brain biopsy procedures that are difficult to carry out clinically, thus breaking through the limitations of clinical experience in diagnosing a-synuclein lineage diseases and greatly improving the diagnostic and differential diagnostic level of this group of diseases.

Clinical needs: α-Synaptic nucleoprotein lineage diseases (Parkinson's disease, multisystem atrophy, and Lewy body dementia) have complex early symptoms, making diagnosis and differential diagnosis difficult. Early diagnosis is crucial for disease prognosis. Authoritative theories suggest that brain tissue biopsy is necessary for the diagnosis of this group of diseases, but it is difficult to generalize in clinical practice. Therefore, there is a 20% misdiagnosis and missed diagnosis rate in the clinical diagnosis of α-synaptic nuclear protein spectrum diseases. The α-Synuclein Ultrafine Fluorescence Detection Method for body fluids and skin in Parkinson's patients can truly reflect the degree of pathological aggregation in synapses, which is helpful for early diagnosis and evaluation of diseases.
An anti-cancer combination containing an antimetabolic medicine and a potentiating agent is a sustained-release injection, which contains a sustained-release microsphere and a menstruum. The sustained-release microsphere contains anti-cancer effective components and sustained-release auxiliary materials; the menstruum is an ordinary menstruum or a special menstruum containing a suspending agent. The viscosity of the suspending agent is 100cp to 3000cp (at the temperature of 20 DEG to 30 DEG) and the suspending agent is selected from carboxymethylcellulose sodium, etc. The antimetabolic medicine is selected from methotrexate, fluorouracil, carmofur, Tegafur, decitabine, capecitabine or Gemcitabine; the potentiating agent is tetrazine medicine and/or anti-cancer antibiotics; the sustained-release auxiliary materials are selected from a polyphosphonate copolymer of p(LAEG-EOP), p(DAPG-EOP) or a copolymer or a mixture of polyphosphate and polylactic acid, polifeprosan, decanedioic acid or PLGA. The anti-cancer combination can also be made into a sustained-release implanting agent, which can be injected or placed in or around tumor to maintain the effective medicine density for more than 50 days. The anti-cancer combination can also obviously reduce the general reaction of the medicine and selectively enhance the curing effect of non-operational therapies such as radiotherapy and chemotherapy.
PURPOSE: A composition containing Aruncus dioicus var. kamtschaticus Hara extract or a fraction thereof for antiviral, antioxidative, or antibacterial effect is provided to be used as a functional foods without side effect. CONSTITUTION: An antiviral composition contains Aruncus dioicus var. kamtschaticus Hara extract or a fraction thereof. An antioxidative composition contains extract or fraction thereof. An antibacterial composition contains the extract or fraction thereof. The ethanol extract is prepared by: adding 2400-3000 weight parts of 70-90% ethanol to 160-240 weight parts of dried Aruncus dioicus var. kamtschaticus Hara, decompressing and concentrating the extract at 30-50°C. The fraction is prepared by n-hexane, chloroform, ethyl acetate, and n-butanol.
A composition comprising iron (ferric or ferrous ions) and at least one vaccine adjuvant. The vaccine adjuvant may be LPS (lipopolysaccharide), monophosphoryl lipid A, a toll-like receptor agonists, Poly IC, a pattern recognition receptor (PRR) ligand, a NOD-like (nucleotide oligomerization domain) receptor ligand, a lectin receptor, alum, MF95, saponin, Quil-A or QS21. The iron may be iron chloride, iron oxides, iron phosphate or iron hydroxide. The composition may be suitable for use in human or veterinary medicine. The composition can be used in combination with an antigen as part of a vaccine or immunomodulatory product. Also claimed is a composition comprising monophosphoryl lipid A and iron (II) chloride (FeCl2). The composition may be used in the preparation of a vaccine or immunomodulatory product. The ambient endotoxin levels in particular matter (PM) from various environments (traffic, green and industrial) was monitored and the ability of host cell immune recognition of LPS was assessed for each sample. Analysis of metals in the environmental samples was carried out. Higher levels of iron was present in traffic samples, where there was highest levels of TLR4 stimulation by LPS.